Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes

Journal of Experimental Medicine

Volumn 199, Issue 4, 2004, Pages 459-470

  Voo, Kui Shin ^a   Fu, Tihui ^a   Wang, Helen Y ^a   Tellam, Judy ^b   Heslop, Helen E ^a   Brenner, Malcolm K ^a   Rooney, Cliona M ^a   Wang, Rong Fu ^a,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen presentation; Cancer vaccines; CD8+ T cells; Immunotherapy; MHC class I restricted peptides

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; LATENT MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; SERINE PROTEINASE;

ANTIGEN PRESENTATION; ARTICLE; CELL TRANSFORMATION; DNA DEGRADATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRUS GENE;

AMINO ACID SEQUENCE; ANTIGEN-ANTIBODY REACTIONS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; PEPTIDE FRAGMENTS;

EID: 1242343722     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031219     Document Type: Article

References (33)

1. Kieff, E. 1995. Epstein-Barr virus-increasing evidence of a link to carcinoma. N. Engl. J. Med. 333:724-726.
2. Rickinson, A.B., and D.J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
3. Rowe, M., D.T. Rowe, C.D. Gregory, L.S. Young, P.J. Farrell, H. Rupani, and A.B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
4. Khanna, R., D.J. Moss, and S.R. Burrows. 1999. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170:49-64.
5. Blake, N., T. Haigh, G. Shaka'a, D. Croom-Carter, and A. Rickinson. 2000. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:7078-7087.
6. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P.M. Steigerwald-Mullen, G. Klein, M.G. Kurilla, and M.G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 375:685-688.
7. Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. Steigerwald-Mullen, M.G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1:HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 7:791-802.
8. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M.G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:12616-12621.
9. Leen, A., P. Meij, I. Redchenko, J. Middeldorp, E. Bloemena, A. Rickinson, and N. Blake. 2001. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol. 75:8649-8659.
10. Paludan, C., K. Bickham, S. Nikiforow, M.L. Tsang, K. Goodman, W.A. Hanekom, J.F. Fonteneau, S. Stevanovic, and C. Munz. 2002. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-1603.
11. Voo, K.S., T. Fu, H.E. Heslop, M.K. Brenner, C.M. Rooney, and R.-F. Wang. 2002. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4+ T cells. Cancer Res. 62:7195-7199.
12. Wang, R.-F., S.L. Johnston, G. Zeng, D.J. Schwartzentruber, and S.A. Rosenberg. 1998. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161:3596-3606.
13. Wang, R.-F., M.R. Parkhurst, Y. Kawakami, P.F. Robbins, and S.A. Rosenberg. 1996. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131-1140.
14. Tan, L.C., N. Gudgeon, N.E. Annels, P. Hansasuta, C.A. O'Callaghan, S. Rowland-Jones, A.J. McMichael, A.B. Rickinson, and M.F. Callan. 1999. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
15. Tellam, J., M. Sherritt, S. Thomson, R. Tellam, D.J. Moss, S.R. Burrows, E. Wiertz, and R. Khanna. 2001. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem. 276:33353-33360.
16. Wang, R.-F., X. Wang, S.L. Johnston, G. Zeng, P.F. Robbins, and S.A. Rosenberg. 1998. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res. 58:3519-3525.
17. Wang, R.-F., X. Wang, A.C. Atwood, S.L. Topalian, and S.A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 284:1351-1354.
18. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191:1649-1660.
19. Steinman, R.M., and M. Dhodapkar. 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 94:459-473.
20. Heath, W.R., and F.R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:47-64.
21. Wang, R.F., and S.A. Rosenberg. 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170:85-100.
22. Rock, K.L., I.A. York, T. Saric, and A.L. Goldberg. 2002. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80:1-70.
23. Gromme, M., F.G. Uytdehaag, H. Janssen, J. Calafat, R.S. van Binnendijk, M.J. Kenter, A. Tulp, D. Verwoerd, and J. Neefjes. 1999. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl. Acad. Sci. USA. 96:10326-10331.
24. Germain, R.N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:287-299.
25. Schubert, U., L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:770-774.
26. Reits, E.A., J.C. Vos, M. Gromme, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 404:774-778.
27. Yewdell, J.W., U. Schubert, and J.R. Bennink. 2001. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J. Cell Sci. 114:845-851.
28. Larsson, M., J.F. Fonteneau, and N. Bhardwaj. 2001. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 22:141-148.
29. Khanna, R., S.R. Burrows, P.M. Steigerwald-Mullen, S.A. Thomson, M.G. Kurilla, and D.J. Moss. 1995. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology. 214:633-637.
30. Shi, Y., and C.T. Lutz. 2002. Interferon-gamma control of EBV-transformed B cells: a role for CD8+ T cells that poorly kill EBV-infected cells. Viral Immunol. 15:213-225.
31. Zhang, D., P. Shankar, Z. Xu, B. Harnisch, G. Chen, C. Lange, S.J. Lee, H. Valdez, M.M. Lederman, and J. Lieberman. 2003. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 101:226-235.
32. Wang, R.-F. 2001. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:269-276.
33. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 301:1371-1374.